Shenling Baizhu San supresses colitis associated colorectal cancer through inhibition of epithelial-mesenchymal transition and myeloid-derived suppressor infiltration

BMC Complementary and Alternative Medicine

Volumn 15, Issue 1, 2015, Pages

  Lin, Xiaochang ^a   Xu, Wenjuan ^a   Shao, Meng ^a   Fan, Qin ^a   Wen, Ge ^a   Li, Changke ^b   Jing, Linlin ^a   Sun, Xuegang ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b YUEBEI PEOPLE S HOSPITAL   (China)

Author keywords

Colitis associated colorectal cancer; Epithelial mesenchymal transition; Myeloid derived suppressor cells; Shenling Baizhu San; Snail; Transforming growth factor 1

Indexed keywords

AZOXYMETHANE; BETA CATENIN; CYCLINE; DEXTRAN SULFATE; FIBRONECTIN; HERBACEOUS AGENT; NERVE CELL ADHESION MOLECULE; PROTEIN P53; SHENLING BAIZHU SAN; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; WNT5A PROTEIN; CADHERIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PREVENTION; CHINESE MEDICINE; COLITIS; COLON; COLON TUMOR; COLORECTAL CANCER; CONTROLLED STUDY; DEATH; DOWN REGULATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; INCIDENCE; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PHENOTYPE; PROTEIN BLOOD LEVEL; SUPPRESSOR CELL; UPREGULATION; WESTERN BLOTTING; ANIMAL; BLOOD; BONE MARROW CELL; C57BL MOUSE; COLORECTAL NEOPLASMS; COMPLICATION; DRUG EFFECTS; HUMAN; METABOLISM; PHYTOTHERAPY;

ANIMALS; AZOXYMETHANE; BETA CATENIN; CADHERINS; COLITIS; COLON; COLORECTAL NEOPLASMS; DEXTRAN SULFATE; DOWN-REGULATION; DRUGS, CHINESE HERBAL; EPITHELIAL-MESENCHYMAL TRANSITION; FIBRONECTINS; HUMANS; MALE; MICE, INBRED C57BL; MYELOID CELLS; PHYTOTHERAPY; PROLIFERATING CELL NUCLEAR ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1; VIMENTIN;

EID: 84929157622     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/s12906-015-0649-9     Document Type: Article

References (40)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-917.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
3. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, et al. Prognostic factors in colorectal cancer. College of American pathologists consensus statement. Arch Pathol Lab Med 2000. 1999;124(7):979-94.
4. Lu KQ. [The applicatiion of Shenling Baizhu Power on postoperational colorectal cancer]. Chin J Med. 2000;35(6):51.
5. Li PX, Jia YJ, Jia YT, Chen J. The observation of Shenling Baizhu San in improving Pi-deficiency postoperation. J Tianjin Coll Tradit Chin Med. 2005;24(3):151-2.
6. Huang ZR, Wang Y, Wang RP, Chen JJ. Effects of Shenling Baizhu San on serum IL-2, INF-γ TNF-α in tumor bearing mice. Guangming J Chin Med. 2010;25(9):1584-6.
7. Li Z. [Changes of cellular immune function in Lewis mice with lung cancer after Shenlingbaizhusan decoction treatment]. J Hainan Med Coll. 2013;19(6):738-42. 745.
8. Tang B. [Clinical observation of Shenling Baizhu San on 60 cases of chronic enteritis]. Intern Med China. 2011;6(3):225-6.
9. Li XM. [Clinical observation of the efficacy of Shenling Baizhu powder on treatment of chronic enteritis]. China Mod Med. 2012;19(15):90-1.
10. Garrett WS, Punit S, Gallini CA, Michaud M, Zhang D, Sigrist KS, et al. Colitis-associated colorectal cancer driven by T-bet deficiency in dendritic cells. Cancer Cell. 2009;16(3):208-19.
11. Zhu QC, Gao RY, Wu W, Qin HL. Epithelial-mesenchymal transition and its role in the pathogenesis of colorectal cancer. Asian Pac J Cancer Prev. 2013;14(5):2689-98.
12. Kawakami Y, Yaguchi T, Sumimoto H, Kudo-Saito C, Iwata-Kajihara T, Nakamura S, et al. Improvement of cancer immunotherapy by combining molecular targeted therapy. Front Oncol. 2013;3:136.
13. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024):1565-70.
14. Toh B, Wang X, Keeble J, Sim WJ, Khoo K, Wong WC, et al. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol. 2011;9(9):e1001162.
15. Li H, Wu WK, Li ZJ, Chan KM, Wong CC, Ye CG, et al. 2,3',4,4',5'-Pentamethoxy-trans-stilbene, a resveratrol derivative, inhibits colitis-associated colorectal carcinogenesis in mice. Br J Pharmacol. 2010;160(6):1352-61.
16. Lin X, Yi Z, Diao J, Shao M, Zhao L, Cai H, et al. ShaoYao decoction ameliorates colitis-associated colorectal cancer by downregulating proinflammatory cytokines and promoting epithelial-mesenchymal transition. J Transl Med. 2014;12(1):105.
17. Attisano L, Wrana JL. Signal integration in TGF-beta, WNT, and Hippo pathways. F1000Prime Rep. 2013;5:17.
18. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118(3):285-96.
19. Yazlovitskaya EM, DeHaan RD, Persons DL. Prolonged wild-type p53 protein accumulation and cisplatin resistance. Biochem Biophys Res Commun. 2001;283(4):732-7.
20. Amini NS, Ebrahim RP, Van Dam K, Cassiman JJ, Tejpar S. TGF-beta modulates beta-Catenin stability and signaling in mesenchymal proliferations. Exp Cell Res. 2007;313(13):2887-95.
21. Derynck R, Muthusamy BP, Saeteurn KY. Signaling pathway cooperation in TGF-beta-induced epithelial-mesenchymal transition. Curr Opin Cell Biol. 2014;31C:56-66.
22. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871-90.
23. Bhangu A, Wood G, Mirnezami A, Darzi A, Tekkis P, Goldin R. Epithelial mesenchymal transition in colorectal cancer: Seminal role in promoting disease progression and resistance to neoadjuvant therapy. Surg Oncol. 2012;21(4):316-23.
24. Wang H, Wang HS, Zhou BH, Li CL, Zhang F, Wang XF, et al. Epithelial-mesenchymal transition (EMT) induced by TNF-alpha requires AKT/GSK-3beta-mediated stabilization of snail in colorectal cancer. PLoS One. 2013;8(2):e56664.
25. Schwitalla S, Ziegler PK, Horst D, Becker V, Kerle I, Begus-Nahrmann Y, et al. Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. Cancer Cell. 2013;23(1):93-106.
26. Serra R, Easter SL, Jiang W, Baxley SE. Wnt5a as an effector of TGFbeta in mammary development and cancer. J Mammary Gland Biol Neoplasia. 2011;16(2):157-67.
27. Katoh M, Katoh M. Transcriptional mechanisms of WNT5A based on NF-kappaB, Hedgehog, TGFbeta, and Notch signaling cascades. Int J Mol Med. 2009;23(6):763-9.
28. Dissanayake SK, Wade M, Johnson CE, O'Connell MP, Leotlela PD, French AD, et al. The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem. 2007;282(23):17259-71.
29. Sipos F, Galamb O. Epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions in the colon. World J Gastroenterol. 2012;18(7):601-8.
30. Bo H, Zhang S, Gao L, Chen Y, Zhang J, Chang X, et al. Upregulation of Wnt5a promotes epithelial-to-mesenchymal transition and metastasis of pancreatic cancer cells. BMC Cancer. 2013;13(1):496.
31. Thakur N, Gudey SK, Marcusson A, Fu JY, Bergh A, Heldin CH, et al. TGFbeta-induced invasion of prostate cancer cells is promoted by c-Jun-dependent transcriptional activation of Snail1. Cell Cycle. 2014;13(15):2400-14.
32. Fu Y, Liu X, Zhou N, Du L, Sun Y, Zhang X, et al. MicroRNA-200b stimulates tumour growth in TGFBR2-null colorectal cancers by negatively regulating p27/kip1. J Cell Physiol. 2013;229(6):772-82.
33. Sevko A, Umansky V. Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves. J Cancer Educ. 2013;4(1):3-11.
34. Beauchemin N. The colorectal tumor microenvironment: the next decade. Cancer Microenviron. 2011;4(2):181-5.
35. Kanterman J, Sade-Feldman M, Baniyash M. New insights into chronic inflammation-induced immunosuppression. Semin Cancer Biol. 2012;22(4):307-18.
36. Chen Z, Chen LY, Wang P, Dai HY, Gao S, Wang K. Tumor microenvironment varies under different TCM ZHENG models and correlates with treatment response to herbal medicine. Evid Based Complement Alternat Med. 2012;2012:635702.
37. Wang W, Zhang X, Qin JJ, Voruganti S, Nag SA, Wang MH, et al. Natural product ginsenoside 25-OCH3-PPD inhibits breast cancer growth and metastasis through down-regulating MDM2. PLoS One. 2012;7(7):e41586.
38. Cai JP, Wu YJ, Li C, Feng MY, Shi QT, Li R, et al. Panax ginseng polysaccharide suppresses metastasis via modulating Twist expression in gastric cancer. Int J Biol Macromol. 2013;57:22-5.
39. Jeon C, Kang S, Park S, Lim K, Hwang KW, Min H. T cell stimulatory effects of Korean Red ginseng through modulation of myeloid-derived suppressor cells. J Ginseng Res. 2011;35(4):462-70.
40. Bissell MJ, Hines WC. Why don't we get more cancer? a proposed role of the microenvironment in restraining cancer progression. Nat Med. 2011;17(3):320-9.